Danaher Corporation (NYSE:DHR) issued its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05, Bloomberg Earnings reports. The firm had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.47 billion. Danaher Corporation had a return on equity of 11.29% and a net margin of 13.36%. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.87 EPS. Danaher Corporation updated its FY17 guidance to $3.96-4.00 EPS.
Shares of Danaher Corporation (DHR) traded up 0.86% on Friday, hitting $92.25. The stock had a trading volume of 2,875,447 shares. The firm’s 50-day moving average price is $87.12 and its 200 day moving average price is $84.38. The firm has a market cap of $64.09 billion, a PE ratio of 29.44 and a beta of 1.03. Danaher Corporation has a 52-week low of $76.27 and a 52-week high of $92.26.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were paid a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.61%. The ex-dividend date of this dividend was Thursday, September 28th. Danaher Corporation’s payout ratio is 16.52%.
In other Danaher Corporation news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the sale, the insider now directly owns 155,520 shares of the company’s stock, valued at approximately $12,718,425.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Daniel L. Comas sold 88,184 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total value of $8,026,507.68. Following the sale, the chief financial officer now directly owns 227,816 shares of the company’s stock, valued at $20,735,812.32. The disclosure for this sale can be found here. Insiders sold a total of 163,411 shares of company stock valued at $14,431,927 over the last three months. Company insiders own 12.20% of the company’s stock.
A number of brokerages recently weighed in on DHR. Robert W. Baird upped their price objective on Danaher Corporation from $87.00 to $97.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. Morgan Stanley upped their price objective on Danaher Corporation from $95.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, October 20th. Credit Suisse Group upped their price objective on Danaher Corporation from $93.00 to $96.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. Zacks Investment Research upgraded Danaher Corporation from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a research note on Thursday, October 5th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and issued a $95.00 price target on shares of Danaher Corporation in a research note on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $93.31.
TRADEMARK VIOLATION NOTICE: “Danaher Corporation (DHR) Releases Earnings Results, Beats Expectations By $0.05 EPS” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/28/danaher-corporation-dhr-posts-quarterly-earnings-results.html.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.